SK Biopharmaceuticals
Update in progress326030.KS (KSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
SK Biopharmaceuticals Co., Ltd. is a South Korean pharmaceutical company focused on researching, developing and commercializing drugs for central nervous system disorders. It markets Cenobamate for epilepsy and Solriamfetol, and is developing a pipeline that includes Carisbamate (Phase 3 for Lennox-Gastaut syndrome), Relenopride (Phase 2 for a rare neurological disease), and several early-stage candidates such as SKL24741, SKL20540, SKL27969, SKL13865 and SKL-PSY for various CNS conditions. Founded 1993, based in Seongnam, and a subsidiary of SK Inc.
Company score
- Sentiment
- 0.55
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.32
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.12
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.33
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketKSE (KSC)
- LocationSouth Korea
- CEOMr. Dong Hoon Lee
- Founded1993
- Websitewww.skbp.com
Identifiers
- ISINKR7326030004